CorMedix 8K Other Events | CRMD 3 Dec 13

EXHIBIT 99.1

DRIVES EVERYTHING WE DO

Company Overview

NYSE MKT: CRMD

December 2013

Forward Looking Statements

This presentation contains certain statements that constitute forward-looking statements
within the meaning of the federal securities laws. Statements that are not historical
facts, including statements about our beliefs and expectations, are forward-looking
statements. These statements are not guarantees of future performance and involve
risks, uncertainties and assumptions that are difficult to predict. The forward looking
statements in this presentation include statements about our business, including
commercialization plans and potential markets for our products and product candidates,
clinical trials, potential indications for our product candidates, development timelines,
regulatory timelines and future events that have not yet occurred. Pharmaceutical and
medical device development inherently involves significant risks and uncertainties,
including the risks outlined in “Risk Factors” in our Annual Report on Form 10-K filed
with the Securities and Exchange Commission on March 27, 2013 and in “Risk Factors”
in our Quarterly Reports on Form 10-Q filed with the Securities and Exchange
Commission on May 15 and August 14, 2013. Our actual results may differ materially
from our expectations due to these risks and uncertainties, including, but not limited to,
our dependence on the success of our lead product candidate, and factors relating to
commercialization and regulatory approval thereof, ability to raise sufficient capital,
retaining our stock’s listing on the NYSE MKT, research and development activities,
intellectual property protection, competition, industry environment, and other matters.
Any forward-looking statements included in this presentation are based on information
available to us on the date of this presentation. We undertake no obligation to update or
revise any forward-looking statement, whether as a result of new information, future
events or otherwise.

Investment Highlights

CorMedix (NYSE MKT: CRMD) develops and markets
products to treat renal, cardiac and infectious diseases

Lead product Neutrolin®

Class III CE Mark approved (drug-device) in July 2013

Catheter-related bloodstream infections (CRBSI)

cost approx. $25,000-40,000/hospitalization, or $6+ B/year, in the US

Clear European commercialization strategy

specialized and highly experienced EU sales force

Using a catheter lock solution (CLS) such as Neutrolin can reduce
occurrence of CRBSI by as much as 60-90 percent

$500M worldwide market potential

Solid Global IP portfolio

17 issued U.S. patents

Catheter Safety and Efficacy:

15 Million

80,000

$25,000-
40,000

$6+ Billion

Total CRBSI cost to the
U.S. healthcare system

per year

By the Numbers

250,000

Estimated CRBSI
across all

hospitals

Sources: U.S. Centers for Disease Control and Prevention. Trish Perl, M.D., professor, medicine and pathology, Johns Hopkins School
of Public Health, Baltimore; Eyal Zimlichman, M.D., research associate, The Center for Patient Safety, Brigham and Women's Hospital,
Boston; Sept. 2, 2013, JAMA Internal Medicine, online

What could save the US Healthcare system

Billions per year?

Neutrolin®

A Catheter Lock Solution (CLS)
that fills the catheter to:

• Significantly decrease CRBSI

• Decrease catheter blood clotting
episodes

Neutrolin® contains:

• Taurolidine, an anti-infective

• Citrate, a buffering compound

• Heparin, an anticoagulant

Neutrolin®
Mechanism of Action

Taurolidine: a taurine amino acid
derivative

• Shows broad antibacterial action
against gram-positive and gram-
negative bacteria, mycobacteria and
some clinically relevant fungi

• Shows a higher affinity than
mannose (the natural substrate) for
bacterial fimbriae protein responsible
for bacterial adhesion to human cells

Source: Caruso F, Darnowski JW, Opazo C, Goldberg A, Kishore N, et al. (2010) Taurolidine Antiadhesive Properties on Interaction with E. coli; Its
Transformation in Biological Environment and Interaction with Bacteria Cell Wall. PLoS ONE 5(1): e8927. doi:10.1371/journal.pone.0008927

Why is Antimicrobial Resistance a Problem?

• Antibiotic/antimicrobial resistant infections cause:

– prolonged illness

– greater risk of death

– higher treatment costs

• A high percentage of hospital-acquired infections are
caused by highly resistant microorganisms

– Dialysis patients with catheters are susceptible to biofilm, which
nurtures and protects bacterial and fungal cell growth

– Neutrolin® controls bacteria growth in biofilm

Source: World Health Organization

Taurolidine-Based Catheter Lock Solution:
Demonstrated Effectiveness

*From 58 patients

1. Allon M Clin Infect Dis (2003) 36 (12):1539-44, 2. Betjes Nephrol Dial Transplant (2004) 19:1546-1551, 3. Sodemann K et al Poster: ASN 2001, 4. Bisseling, T. M., M. C. Willems, et al. (2010)
Clin Nutr 29(4): 464-8 , 5.Al-Amin, A. H., J. Sarveswaran, et al. (2013). J Vasc Access 0(0): 0., 6.Chu, H. P., J. Brind, et al. (2012). J Pediatr Gastroenterol Nutr 55(4): 403-7, 7Handrup, M. M.,
J. K. Moller, et al. (2013). Pediatr Blood Cancer 60(8): 1292-8

Successful EU Launch for Hemodialysis

Label Expansion in EU

Rollout to Other Key Countries

Neutrolin Growth Strategy

Entry into US Market for Hemodialysis

Initial Neutrolin Indication:

Hemodialysis

Possible expanded Indications:

Oncology, ICU, Parenteral Nutrition, Peritoneal Dialysis

Strategy:
Successful EU Launch for Hemodialysis

• Successful launch in Germany and Austria

– Experienced sales team

– Increase healthcare provider awareness

– Sales being booked: not yet shipped

• Negotiate partner arrangements

• Position Neutrolin® strategically

– Pricing

– Understand payer reimbursement policies

Strategy:
Rollout to Other Key Countries

• Identify best sales partners in
key countries

• Complete agreements

• Monitor product positioning
and coordinate manufacturing
capacity

Strategy:
Entry Into US Market

• U.S. FDA discussions (pre-IND meeting, timelines)

– FDA clinical trial requirements

• Duration

• Clinical trial execution decision

• Strategic partner

Neutrolin Growth Strategy

Phase I: Europe for Hemodialysis and label expansions

Phase II: Other key countries for Hemodialysis

Phase III: Hemodialysis in the U.S.

$130M

Hemodialysis - Defined Market

Label Expansions - Defined Market
(oncology, ICU, total parenteral nutrition and
peritoneal dialysis)

$130M

$80M

$15M

$30M

$20M

$15M

$100M

$130M

Hemodialysis - Upside Potential

Label Expansions - Upside Potential
(oncology, ICU, total parenteral nutrition and
peritoneal dialysis)

European Union

Rest of World (Ex. US)

United States

IP Status Update

• Global Patent Portfolio - 17 issued
patents provide protection through 2019-
2025

– Freedom to Operate in Europe

– Proprietary

• Planned additional filings

Financial Information

• Total Pro Forma cash of
approximately $3.3 million
as of September 30, 2013

• Total Pro Forma debt of
approximately $0.3 million
as of September 30, 2013

• Capitalized to fund
operations through the
second quarter of 2014
assuming no sales and/or
strategic partnerships

• Approximately 16 million
common shares
outstanding as of
September 30, 2013

Investment Highlights

CorMedix (NYSE MKT: CRMD) develops and markets
products to treat renal, cardiac and infectious diseases

Lead product Neutrolin®

Class III CE Mark approved (drug-device) in July 2013

Catheter-related bloodstream infections (CRBSI)

cost approx. $25,000-40,000/hospitalization, or $6+ B/year, in the US

Clear European commercialization strategy

specialized and highly experienced EU sales force

Using a catheter lock solution (CLS) such as Neutrolin can reduce
occurrence of CRBSI by as much as 60-90 percent

$500M worldwide market potential

Solid Global IP portfolio

17 issued U.S. patents

745 Route 202-206
Suite 303

Bridgewater, NJ 08807

908.517.9500 (ph)

908.429.4307 (fax)

NYSE MKT: CRMD

@CorMedix

rmilby@cormedix.com

Thank You
November 2013

CorMedix (CRMD) 8-KOther Events